Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of VELCADE (Bortezomib) for Steroid Refractory Acute GVHD.

Trial Profile

Phase II Trial of VELCADE (Bortezomib) for Steroid Refractory Acute GVHD.

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2016 Last checked against ClinicalTrials.gov record.
    • 08 Jun 2011 Primary endpoint added according to ClinicalTrials.gov.
    • 08 Jun 2011 Additional lead trial investigator (John Wagner) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top